OMEZA Holdings Licenses OCM™ to Hikma in Select MENA Markets
OMEZA Holdings Inc. has signed an exclusive licensing agreement with Hikma Pharmaceuticals, granting Hikma rights to market and distribute OCM™ in select Middle Eastern and North African markets.
Sarasota, Florida – OMEZA Holdings Inc. announced it has entered into an exclusive licensing agreement with Hikma Pharmaceuticals. The agreement provides Hikma, the largest pharmaceutical company in the Middle East and North Africa (MENA) by sales, with rights to market and distribute OCM™ (OMEZA Complete...) in selected markets within the region.
The partnership is expected to enhance patient access to OCM™ in these key territories. For OMEZA Holdings, this collaboration represents a significant step in its international growth strategy.
Financial terms and specific timelines for the agreement were not disclosed. Both companies have indicated that the collaboration aims to improve the availability of OCM™ for patients.
OMEZA Holdings focuses on the development and commercialization of novel therapeutics. Hikma Pharmaceuticals is recognized for its established presence and distribution network across the MENA healthcare sector.